Opinion|Videos|September 3, 2024
Real-World Treatment of BPH: Outcomes and Patient Education
Fact checked by: Dean Elterman, MD, MSc
Dean Elterman, MD, discusses real-world outcomes of minimally invasive surgical therapies for benign prostate dysplasia, including improvements in quality of life, symptom relief, comparisons with clinical study results, and general patient feedback, while also sharing tips for building rapport and educating patients on their treatment options.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- Please speak to the real-world outcomes of minimally invasive surgical therapy treatments for benign prostate dysplasia you observe in your practice:
- How do outcomes improve patients’ quality of life and other symptoms?
- How do real-world results compare with what various clinical studies have shown?
- Please share general feedback highlights you receive from patients.
- We have already discussed the importance of patient preference in choosing the best treatment. Do you have any tips for how to build rapport and educate patients on their options?
Advertisement
Related to this article
These FAQs outline key recommendations from ASTRO's updated guideline on shorter-course radiation therapy for localized prostate cancer.
Patient goals, disease features, and response to prior therapy guide treatment choices across high-risk NMIBC, according to Suzanne B. Merrill, MD, FACS.
Suzanne B. Merrill, MD, discusses emerging perioperative approaches in MIBC and the potential for more personalized treatment selection based on disease characteristics.
BCG monotherapy and a high-quality TURBT remain the foundation for BCG-naive high-risk NMIBC, according to Vignesh T. Packiam, MD.
Independent urology practices head into 2027 facing a conversion factor cut, prior authorization hurdles, and Part B drug price negotiation, according to Gary Kirsh, MD.
Updated CAPItello-281 data support capivasertib plus abiraterone in PTEN-deficient mHSPC, according to Daniel J. George, MD.
Benjamin Garmezy, MD, discusses personalizing mHSPC treatment intensification based on disease burden, molecular biomarkers, and patient-specific factors.
Patient priorities and practice logistics should guide therapy selection in BCG-unresponsive NMIBC, according to Katie S. Murray, DO, MS, FACS.
Advertisement
Advertisement
Trending on Urology Times
1
Patient priorities guide treatment choice in BCG-unresponsive NMIBC
2
Modern BCG outperforms historic benchmarks in high-risk NMIBC
3
Q&A: Gary Kirsh, MD, on health policy for independent urology
4
Suzanne B. Merrill, MD, on the evolving perioperative landscape in MIBC
5